Testing how much ASTX727 can be given safely for IDH mutant gliomas that came back or kept growing
Official title: ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing a drug called ASTX727 to find the highest dose people can take safely.
Read our full plain-language summary
What the trial team says
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
Key facts
- Registry number
- NCT03922555
- Stage of testing
- Phase 1
- Conditions studied
- Neurological Cancer
Where it is running
This trial lists 3 sites.
-
Massachusetts
- Massachusetts General Hospital Cancer Center (Boston)
- Brigham and Women's Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.